



Kilitch Drugs (India) Ltd.

31st December, 2022

To,
The Manager - Corporate Relationship Dept.
BSE Limited
P. J. Towers, Dalal Street
Fort, Mumbai - 400 001

To,
The Manager - Corporate Compliance
National Stock Exchange of India Ltd
Exchange Plaza, Plot No.C-1, G Block,
BKC, Bandra (E), Mumbai 400 051

Scrip Code: BSE - 524500

Scrip Code: NSE - KILITCH

Sub: Disclosure Pursuant to Regulation 30 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015

Dear Sir,

Pursuant to provisions of regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby would like to inform you that the Company has made additional investment of USD 2,68,000 to acquire equity shares of Kilitch Estro Biotech PLC, foreign subsidiary of the Company to meet working capital requirement of the Company.

We request you to kindly take the same on record and acknowledge the receipt.

Thanking you,

Yours Faithfully,

For **Kilitch Drugs (India) Limited**

**MUKUND
PRATAPRAI
MEHTA**

Digitally signed by MUKUND PRATAPRAI MEHTA
DN: c=IN, o=PERSONAL,
pseudonym=de3699b434193d53a7b94312dfa
7895516e6999e256227966a31143c2144ac,
postalCode=400037, st=MAHARASHTRA,
serialNumber=42eb6fed093b1ff1d748907a2c
221a9f5365516007a4314c168bade189c249f,
cn=MUKUND PRATAPRAI MEHTA
Date: 2022.12.31 12:25:12 +05'30'

**Mukund Mehta
Managing Director**

